Cross-Sector entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Biosidus, the most common co-covered peer. Mubadala Bio appears in 1 tracked Cross-Sector story from July 27, 2026. The tracked stories average 1 original source each.
1 verified story tracked
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Biosidus, the most common co-covered peer. Mubadala Bio appears in 1 tracked Cross-Sector story from July 27, 2026. The tracked stories average 1 original source each.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Mubadala Bio. Shared-story counts are live from our verified record — not editorial picks.
Biosidus, a Latin American biotech, signed a licensing deal with Mubadala Bio at BIO 2026 to introduce four biologic therapies—including epoetin alfa and filgrastim—into the UAE via DiabTec. The move advances local pharma manufacturing and expands Biosidus' global footprint.
Source: prnewswire.com
